| Literature DB >> 33412144 |
Etienne Cavalier1, Samuel Vasikaran2, Harjit P Bhattoa3, Annemieke C Heijboer4, Konstantinos Makris5, Candice Z Ulmer6.
Abstract
Parathyroid hormone (PTH) determination is of greatest importance for patients suffering from parathyroid gland disorders and for the follow-up of bone turnover in patients suffering from chronic kidney disease (CKD). Two generations of PTH assays are simultaneously present on the market for PTH quantification. As these assays are not yet standardized, this results in a significant level of confusion in the care of CKD patients. One key objective of the IFCC Committee for Bone Metabolism is to improve this situation. In this position paper, we will highlight the current state of PTH testing and propose a pathway to ultimately overcome issues resulting from PTH assay variability.Entities:
Keywords: Immunoassays; Parathyroid hormone; Standardization
Mesh:
Substances:
Year: 2021 PMID: 33412144 PMCID: PMC7920929 DOI: 10.1016/j.cca.2020.12.022
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786